Putative dual inhibitors of Janus kinase 1 and 3 (JAK1/3): Pharmacophore based hierarchical virtual screening

Janus kinase 1 and 3 are non-receptor protein tyrosine kinases, involved in the regulation of various cytokines implicated in the pathogenesis of autoimmune and inflammatory disease conditions. Thus, they serve as therapeutic targets for the designing of multi-targeted agents for the treatment of inflammatory-mediated pathological conditions. In the present study, diverse inhibitors of JAK1 and JAK3 were considered for the development of ligand-based pharmacophore models, followed by docking analysis to design putative dual inhibitors. The pharmacophore models were generated in PHASE 3.4, and top five models for each target were selected on the basis of survival minus inactive score. The best model for JAK1 (AAADH.25) and JAK3 (ADDRR.142) were selected corresponding to the highest value of Q2test. Both models were employed for the screening of a PHASE database, and subsequently, the retrieved hits were filtered employing molecular docking in JAK1 and JAK3 proteins. The stable interactions between retrieved hits and proteins were confirmed using molecular dynamics simulations. Finally, ADME properties of screened dual inhibitors displaying essential interactions with both proteins were calculated. Thus, the new leads obtained in this way may be prioritized for experimental validation as potential novel therapeutic agents in the treatment of various autoimmune and inflammatory disorders related to JAK1 and JAK3.

[1]  T. Boggon,et al.  Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.

[2]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[3]  Jane R Kenny,et al.  Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2. , 2012, Bioorganic & medicinal chemistry letters.

[4]  Eric Vangrevelinghe,et al.  Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[5]  Martin Aringer,et al.  Characterization and Analysis of the Proximal Janus Kinase 3 Promoter1 , 2003, The Journal of Immunology.

[6]  Xin Chen,et al.  Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses. , 2009, Bioorganic & medicinal chemistry letters.

[7]  S Sen,et al.  The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma , 2011, Blood cancer journal.

[8]  David S. Nirschl,et al.  Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3. , 2011, Bioorganic & medicinal chemistry letters.

[9]  Xin Huang,et al.  Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. , 2011, Journal of medicinal chemistry.

[10]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[11]  Jane R Kenny,et al.  Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. , 2012, Journal of medicinal chemistry.

[12]  Om Silakari,et al.  Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach , 2013, Molecular Diversity.

[13]  Jitender Verma,et al.  3D-QSAR in drug design--a review. , 2010, Current topics in medicinal chemistry.

[14]  K. West,et al.  CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. , 2009, Current opinion in investigational drugs.

[15]  Alam Jahangir,et al.  3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models. , 2013, Journal of medicinal chemistry.

[16]  Bohdan Waszkowycz,et al.  Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. , 2012, Journal of medicinal chemistry.

[17]  O. Silakari,et al.  Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2 , 2014, SAR and QSAR in environmental research.

[18]  Eric Vangrevelinghe,et al.  2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[19]  W. Pitts,et al.  Chapter 12 Advances in the Discovery of Small Molecule JAK3 Inhibitors , 2009 .

[20]  David M. Shackleford,et al.  Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). , 2009, Bioorganic & medicinal chemistry letters.

[21]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[22]  Eric Vangrevelinghe,et al.  Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. , 2011, Journal of medicinal chemistry.

[23]  Maria L Webb,et al.  Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges , 2008 .

[24]  Jongwon Lim,et al.  Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. , 2011, Journal of medicinal chemistry.

[25]  Clive McCarthy,et al.  Mapping the kinase domain of Janus Kinase 3. , 2003, Bioorganic & medicinal chemistry letters.

[26]  David J Diller,et al.  2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[27]  B. Klebansky,et al.  Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3. , 2010, Bioorganic & medicinal chemistry letters.

[28]  Peter Lipsky,et al.  Cytokines and their role in lymphoid development, differentiation and homeostasis , 2002, Current opinion in allergy and clinical immunology.

[29]  James R Kiefer,et al.  Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. , 2010, Journal of molecular biology.

[30]  Biswanath De,et al.  Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3. , 2006, Bioorganic & medicinal chemistry letters.

[31]  A. Tefferi,et al.  CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.

[32]  Yan Gao,et al.  T cell-intrinsic role of IL-6 signaling in primary and memory responses , 2014, eLife.

[33]  Massimo Gadina,et al.  Jakpot! New small molecules in autoimmune and inflammatory diseases , 2014, Experimental dermatology.

[34]  Biswanath De,et al.  Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3). , 2007, Bioorganic & medicinal chemistry letters.